UCB (UCBJF) recently presented data from a study showing the effect of Neupro on cardiovascular measures in patients with restless legs syndrome (RLS).
The double-blind, placebo-controlled study showed reduction in total nocturnal systolic...
(Nasdaq: IMMU),a biopharmaceutical company primarily focused on the development
of monoclonal antibody-based products for the targeted treatment of cancer,
autoimmune and other serious diseases, today reported that UCB...
NYSE Euronext (NYX) today announced a successful €250 million bond issue on its Brussels-market by UCB, the Belgium-based global biopharmaceutical group.
UCB focuses on the discovery and development of innovative medicines and solutions to...
UCB (UCBJF) recently announced that it has licensed exclusive global rights to tozadenant (SYN115) for Parkinson’s disease from Biotie Therapies.
Tozadenant is an orally administered, selective inhibitor of the adenosine 2a...
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to UCB SA (UCB-BT):